AstraZeneca.
119 announcements.
119 announcements.
| Time | Date | Ticker | Company | Announcement |
|---|---|---|---|---|
| 13:45 | 04-12-2024 | AZN | AstraZeneca | AstraZeneca appoints Iskra Reic EVP International |
| 15:05 | 02-12-2024 | AZN | AstraZeneca | Block listing Interim Review |
| 15:00 | 02-12-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 25-11-2024 | AZN | AstraZeneca | Truqap improved rPFS in advanced prostate cancer |
| 16:00 | 20-11-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 18-11-2024 | AZN | AstraZeneca | Tagrisso recommended for EU approval - LAURA |
| 14:00 | 15-11-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 10:00 | 15-11-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 16:00 | 13-11-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:05 | 12-11-2024 | AZN | AstraZeneca | KOMET Phase III trial met primary endpoint |
| 07:00 | 12-11-2024 | AZN | AstraZeneca | 9M and Q3 2024 Results |
| 07:00 | 12-11-2024 | AZN | AstraZeneca | Dato-DXd new BLA submitted, NSQ BLA withdrawn |
| 07:10 | 12-11-2024 | AZN | AstraZeneca | AstraZeneca invests $3.5 billion in US |
| 07:00 | 08-11-2024 | AZN | AstraZeneca | Tezspire nasal polyps trial met primary endpoints |
| 16:49 | 05-11-2024 | AZN | AstraZeneca | AZN share price movement |
| 15:00 | 01-11-2024 | AZN | AstraZeneca | Total Voting Rights |
| 13:00 | 30-10-2024 | AZN | AstraZeneca | AZN China President under investigation |
| 07:00 | 21-10-2024 | AZN | AstraZeneca | Wainzua recommended for approval in the EU |
| 09:30 | 07-10-2024 | AZN | AstraZeneca | AstraZeneca licenses lipid lowering Lp(a) asset |
| 15:00 | 01-10-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 26-09-2024 | AZN | AstraZeneca | Tagrisso US approval in unresectable lung cancer |
| 07:00 | 23-09-2024 | AZN | AstraZeneca | Final OS results reported for TROPION-Breast01 |
| 07:05 | 23-09-2024 | AZN | AstraZeneca | Fasenra recommended for EU approval in EGPA |
| 07:00 | 18-09-2024 | AZN | AstraZeneca | Fasenra EGPA US FDA approval |
| 15:15 | 13-09-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 15:00 | 02-09-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 16-08-2024 | AZN | AstraZeneca | Imfinzi approved in US for resectable lung cancer |
| 15:00 | 01-08-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 26-07-2024 | AZN | AstraZeneca | ODAC reviewed Imfinzi in resectable lung cancer |
| 07:00 | 25-07-2024 | AZN | AstraZeneca | Half-year Report |
| 07:00 | 15-07-2024 | AZN | AstraZeneca | Acquisition of Amolyt Pharma completed |
| 15:00 | 01-07-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 01-07-2024 | AZN | AstraZeneca | Lynparza & Imfinzi positive CHMP in endometrial |
| 07:05 | 25-06-2024 | AZN | AstraZeneca | Update on Imfinzi ADJUVANT BR.31 trial |
| 07:00 | 25-06-2024 | AZN | AstraZeneca | Imfinzi improved EFS and OS in bladder cancer |
| 07:00 | 18-06-2024 | AZN | AstraZeneca | Update on CAPItello-290 Phase III trial |
| 07:00 | 17-06-2024 | AZN | AstraZeneca | Imfinzi approved in the US for endometrial cancer |
| 15:00 | 12-06-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 05-06-2024 | AZN | AstraZeneca | Acquisition of Fusion completed |
| 15:05 | 03-06-2024 | AZN | AstraZeneca | Block listing Interim Review |
| 15:00 | 03-06-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 03-06-2024 | AZN | AstraZeneca | Tagrisso plus chemo recommended for approval in EU |
| 07:00 | 28-05-2024 | AZN | AstraZeneca | Dato-DXd improved OS in nonsquamous lung cancer |
| 07:00 | 21-05-2024 | AZN | AstraZeneca | AstraZeneca to deliver $80bn revenue by 2030 |
| 07:00 | 16-05-2024 | AZN | AstraZeneca | SUPERNOVA Trial Met COVID-19 prevention endpoint |
| 15:00 | 15-05-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 07-05-2024 | AZN | AstraZeneca | AstraZeneca completes Cellectis equity investment |
| 07:00 | 02-05-2024 | AZN | AstraZeneca | Calquence combination improved PFS in 1L MCL |
| 15:00 | 01-05-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:05 | 29-04-2024 | AZN | AstraZeneca | Truqap recommended for EU breast cancer approval |
| 07:00 | 29-04-2024 | AZN | AstraZeneca | Enhertu improved PFS in HER2-low and ultralow |
| 07:00 | 25-04-2024 | AZN | AstraZeneca | 1st Quarter Results |
| 17:30 | 11-04-2024 | AZN | AstraZeneca | Result of AGM |
| 07:00 | 11-04-2024 | AZN | AstraZeneca | AstraZeneca increases 2024 dividend by 7% |
| 07:00 | 08-04-2024 | AZN | AstraZeneca | Enhertu approved in US for HER2+ solid tumours |
| 07:00 | 05-04-2024 | AZN | AstraZeneca | Imfinzi improved OS & PFS in limited-stage SCLC |
| 15:00 | 02-04-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 02-04-2024 | AZN | AstraZeneca | FDA accepts Dato-DXd BLA for breast cancer |
| 07:05 | 02-04-2024 | AZN | AstraZeneca | Voydeya approved in US |
| 07:00 | 25-03-2024 | AZN | AstraZeneca | Ultomiris approved in the US for NMOSD |
| 07:00 | 19-03-2024 | AZN | AstraZeneca | AstraZeneca to acquire Fusion |
| 07:00 | 14-03-2024 | AZN | AstraZeneca | AstraZeneca to acquire Amolyt |
| 11:00 | 12-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 11:00 | 07-03-2024 | AZN | AstraZeneca | Notice of AGM |
| 15:00 | 06-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 15:05 | 06-03-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 04-03-2024 | AZN | AstraZeneca | EMA validates Dato-DXd MAAs for NSQ NSCLC and BC |
| 15:00 | 01-03-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 26-02-2024 | AZN | AstraZeneca | Voydeya recommended for EU approval |
| 13:15 | 22-02-2024 | AZN | AstraZeneca | Acquisition of Gracell completed |
| 11:00 | 22-02-2024 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 22-02-2024 | AZN | AstraZeneca | AstraZeneca prices a $5bn bond offering |
| 11:00 | 20-02-2024 | AZN | AstraZeneca | Annual Financial Report |
| 15:00 | 19-02-2024 | AZN | AstraZeneca | AstraZeneca completes acquisition of Icosavax |
| 07:00 | 19-02-2024 | AZN | AstraZeneca | Tagrisso improved PFS in Stage III lung cancer |
| 07:05 | 19-02-2024 | AZN | AstraZeneca | FDA accepts Dato-DXd BLA for nonsquamous NSCLC |
| 07:10 | 19-02-2024 | AZN | AstraZeneca | Tagrisso plus chemo approved in US for lung cancer |
| 07:00 | 08-02-2024 | AZN | AstraZeneca | Final Results |
| 15:00 | 01-02-2024 | AZN | AstraZeneca | Total Voting Rights |
| 15:00 | 02-01-2024 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 27-12-2023 | AZN | AstraZeneca | AstraZeneca acquires Gracell |
| 07:00 | 22-12-2023 | AZN | AstraZeneca | Wainua (eplontersen) granted first US FDA approval |
| 15:00 | 14-12-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:05 | 12-12-2023 | AZN | AstraZeneca | AstraZeneca to acquire Icosavax |
| 15:05 | 01-12-2023 | AZN | AstraZeneca | Block listing Interim Review |
| 15:00 | 01-12-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 01-12-2023 | AZN | AstraZeneca | Discontinuation of two CRYSTALIZE evidence trials |
| 15:00 | 23-11-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 17-11-2023 | AZN | AstraZeneca | Truqap approved in US for HR+ breast cancer |
| 07:05 | 14-11-2023 | AZN | AstraZeneca | Update on PACIFIC-2 Phase III trial for Imfinzi |
| 15:00 | 09-11-2023 | AZN | AstraZeneca | Director Declaration |
| 07:00 | 09-11-2023 | AZN | AstraZeneca | 9M and Q3 2023 results |
| 07:10 | 09-11-2023 | AZN | AstraZeneca | Imfinzi combination improves PFS in liver cancer |
| 07:05 | 09-11-2023 | AZN | AstraZeneca | Agreement with Eccogene for clinical stage GLP-1RA |
| 15:00 | 01-11-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 01-11-2023 | AZN | AstraZeneca | AstraZeneca cell & gene therapy deal w/ Cellectis |
| 07:00 | 03-10-2023 | AZN | AstraZeneca | AstraZeneca settles Nexium liability litigations |
| 15:00 | 02-10-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 22-09-2023 | AZN | AstraZeneca | Dato-DXd improved PFS in breast cancer |
| 07:00 | 20-09-2023 | AZN | AstraZeneca | Alexion completes Pfizer gene therapy agreement |
| 15:00 | 15-09-2023 | AZN | AstraZeneca | Enhertu recommended in EU for HER2-mutant NSCLC |
| 16:00 | 11-09-2023 | AZN | AstraZeneca | Fasenra Phase III EGPA trial met primary endpoint |
| 07:00 | 06-09-2023 | AZN | AstraZeneca | Update on US review of Ultomiris for NMOSD |
| 15:00 | 01-09-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:05 | 28-07-2023 | AZN | AstraZeneca | Alexion enters gene therapy agreement with Pfizer |
| 07:00 | 28-07-2023 | AZN | AstraZeneca | Half-year Report |
| 15:00 | 03-07-2023 | AZN | AstraZeneca | Total Voting Rights |
| 07:00 | 03-07-2023 | AZN | AstraZeneca | Dato-DXd significantly improved PFS in lung cancer |
| 07:05 | 09-06-2023 | AZN | AstraZeneca | nirsevimab recommended for infant RSV protection |
| 07:00 | 09-06-2023 | AZN | AstraZeneca | AstraZeneca agreement with Quell Therapeutics |
| 17:00 | 02-06-2023 | AZN | AstraZeneca | Imfinzi improved pCR in gastric and GEJ cancers |
| 15:00 | 01-06-2023 | AZN | AstraZeneca | Total Voting Rights |
| 15:05 | 01-06-2023 | AZN | AstraZeneca | Block listing Interim Review |
| 07:00 | 01-06-2023 | AZN | AstraZeneca | Lynparza approved in US for BRCAm prostate cancer |
| 07:00 | 26-05-2023 | AZN | AstraZeneca | Imfinzi + Lynparza prolonged PFS in endometrial ca |
| 07:05 | 22-05-2023 | AZN | AstraZeneca | Directorate Change |
| 07:00 | 17-05-2023 | AZN | AstraZeneca | Tagrisso plus chemo improved PFS in lung cancer |
| 11:00 | 09-05-2023 | AZN | AstraZeneca | Director/PDMR Shareholding |
| 07:00 | 09-05-2023 | AZN | AstraZeneca | Farxiga extended in the US for heart failure |